{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001974640","name":"Apogee Therapeutics, Inc.","summary":"Apogee Therapeutics is a clinical-stage biotechnology company developing optimized, novel biologics for inflammatory and immunology (I&I) conditions including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. Its pipeline includes zumilokibart (APG777, anti-IL13), APG279 (zumilokibart + APG990, anti-OX40L), APG273 (zumilokibart + APG333, anti-TSLP), and APG808 (anti-IL-4R), all engineered with extended half-lives to enable infrequent subcutaneous dosing.","people":[],"products":[{"name":"Zumilokibart (APG777)","type":"platform","description":"Subcutaneous extended half-life anti-IL13 monoclonal antibody in Phase 2 for atopic dermatitis and Phase 1b for asthma, with potential for every 3-6 month dosing."},{"name":"APG279","type":"platform","description":"Combination of zumilokibart and APG990 (anti-OX40L), targeting broad Type 1-3 inflammation for atopic dermatitis, in Phase 1b trial."},{"name":"APG990","type":"platform","description":"Subcutaneous extended half-life anti-OX40L monoclonal antibody with ~60-day half-life, component of APG279 combination therapy."},{"name":"APG273","type":"platform","description":"Combination of zumilokibart and APG333 (anti-TSLP), targeting asthma and COPD, planned for quarterly or less frequent dosing."},{"name":"APG333","type":"platform","description":"Subcutaneous extended half-life anti-TSLP monoclonal antibody, component of APG273 combination therapy for asthma and COPD."},{"name":"APG808","type":"platform","description":"Novel half-life extended anti-IL-4R antibody; announced positive interim Phase 1b results in mild-to-moderate asthma patients in May 2025."}],"partnerships":[],"affiliations":[],"origin":{"leaf":"17b1883590cfec229f18193047817a0ebd508f323e726869b237e9921f537197","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"0d965acb10cb13d0a5ab2eea5ddb38420e86e5d8a1e61056c02cf3df7c976ee1","parent":"39d4f8a1b88276bb73a97a9f551451740a98b2bafe21930f39c24fbdadf8fc14","source":"0001974640-26-000002","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":465,"hourly_limit":500,"remaining":35,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}